---
title: "MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278748555.md"
description: "MicroPort CardioFlow Medtech Corp. has announced a change in its reporting currency from Renminbi to U.S. dollars to align with its globalization strategy and the contribution of its subsidiary, MicroPort Cardiac Rhythm Management Limited. This change aims to provide clearer financial performance insights for shareholders and investors, with prior-year figures restated in USD starting with the 2025 annual report. The current analyst rating for the stock (HK:2160) is a Hold, with a price target of HK$0.76."
datetime: "2026-03-11T15:10:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278748555.md)
  - [en](https://longbridge.com/en/news/278748555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278748555.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278748555.md) | [繁體中文](https://longbridge.com/zh-HK/news/278748555.md)


# MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an announcement.

MicroPort CardioFlow Medtech Corporation has announced it will change the presentation currency of its consolidated financial statements from Renminbi to U.S. dollars, reflecting the growing contribution of MicroPort Cardiac Rhythm Management Limited, whose reporting currency is USD. The board says the move supports the Group’s globalization strategy, aims to give shareholders and potential investors a clearer view of its financial performance, and is not expected to have a material impact on the financial statements as prior-year figures will be restated in USD starting with the 2025 annual report.

The most recent analyst rating on (HK:2160) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

**More about MicroPort CardioFlow Medtech Corp.**

MicroPort CardioFlow Medtech Corporation is a Cayman Islands–incorporated medical technology company listed in Hong Kong that operates through subsidiaries in the cardiovascular sector. The Group focuses on cardiac-related therapies and devices, and is pursuing a globalization strategy, including an expanded presence through its cardiac rhythm management business, which reports in U.S. dollars.

**Average Trading Volume:** 1,955,318

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$4.61B

### Related Stocks

- [MICROPORT (00853.HK)](https://longbridge.com/en/quote/00853.HK.md)
- [MP CARDIOFLOW-B (02160.HK)](https://longbridge.com/en/quote/02160.HK.md)
- [MICROPORT NEURO (02172.HK)](https://longbridge.com/en/quote/02172.HK.md)

## Related News & Research

- [MicroPort CardioFlow Reports 350% Year-on-Year Increase in TAVI Implantations for 2025](https://longbridge.com/en/news/271119156.md)
- [MicroPort CardioFlow Medtech Corporation Held Extraordinary General Meeting](https://longbridge.com/en/news/269735980.md)
- [08:50 ETDraper's LEAP Valve Demonstrates Spontaneous "Growth" in Preclinical Studies](https://longbridge.com/en/news/278559695.md)
- [Strong social connections may protect your heart, say cardiologists](https://longbridge.com/en/news/278071280.md)
- [iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential](https://longbridge.com/en/news/278383705.md)